Collins J, Donner A, Allen L H, Adams O
Lancet. 1980 Nov 1;2(8201):961-4. doi: 10.1016/s0140-6736(80)92115-7.
Of 860 women with endometrial cancer registered in a regional cancer treatment centre, 259 (30%) gave a history of oestrogen use for 6 months or more at some time before diagnosis, and 568 (66%) were non-users. OEstrogen use was associated with younger age, earlier stage, lower grade of tumour, less common myometrial invasion, and preferred treatment including radiation and hysterectomy. The 5-year survival of oestrogen users was 92 +/- 2% compared with 68 +/- 2% for non-users. Further analysis controlling for differences in the distribution of the variables associated with survival showed that for women who have endometrial cancer, the risk of any death for non-users is approximately 2-7 times greater than for oestrogen users, and the risk of death from endometrial cancer is 5.4 times greater for non-users. A history of oestrogen use is not associated with superior survival of women who have poorly differentiated tumours or myometrial invasion.
在某地区癌症治疗中心登记的860例子宫内膜癌女性患者中，259例（30%）在诊断前的某个时间有过6个月或更长时间的雌激素使用史，568例（66%）为非使用者。雌激素使用与年龄较轻、分期较早、肿瘤分级较低、肌层浸润较少见以及包括放疗和子宫切除术在内的首选治疗相关。雌激素使用者的5年生存率为92±2%，而非使用者为68±2%。进一步分析控制了与生存相关变量分布的差异，结果显示，对于患有子宫内膜癌的女性，非使用者的任何死亡风险约为雌激素使用者的2 - 7倍，非使用者死于子宫内膜癌的风险是使用者的5.4倍。雌激素使用史与低分化肿瘤或肌层浸润女性的优越生存无关。
